# A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy

> **NCT07541287** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jade Biosciences, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** JADE101

## Key facts

- **NCT ID:** NCT07541287
- **Lead sponsor:** Jade Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-01
- **Final completion:** 2029-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07541287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07541287, "A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07541287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*